This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Dermatology and Therapy Open Access 25 May 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 30, 475–476 (2012). https://doi.org/10.1038/nbt0612-475
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0612-475
This article is cited by
-
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Dermatology and Therapy (2016)
-
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
Oncogene (2015)
-
The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing
Nature Reviews Immunology (2014)
-
Footrace to clinic heats up for T-cell nuclear receptor inhibitors
Nature Biotechnology (2013)
-
The Th17 Pathway as a Therapeutic Target in Rheumatoid Arthritis and Other Autoimmune and Inflammatory Disorders
BioDrugs (2013)